Principles for interactions with biopharmaceutical companies: the development of guidelines for patient advocacy organizations in the field of rare diseases

BACKGROUND: Rare diseases are a global public health concern, affecting an estimated 350 million individuals. Only 5% of approximately 7000 known rare diseases have a treatment, and only about half have a patient advocacy organization. Biopharmaceutical companies face complex challenges in developin...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Orphanet J Rare Dis
Autors principals: Stein, Susan, Bogard, Elizabeth, Boice, Nicole, Fernandez, Vivian, Field, Tessa, Gilstrap, Alan, Kahn, Susan R., Larkindale, Jane, Mathieson, Toni
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2018
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5778794/
https://ncbi.nlm.nih.gov/pubmed/29357903
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13023-018-0761-2
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars